Sponsor

Grifols Therapeutics LLC

United States 8368 Clayton Boulevard, 27520-9464, United States

About the sponsor

Research activity in Alpha-1 antitrypsin deficiency centers on alpha1-proteinase inhibitor replacement, including subcutaneous and intravenous administration in people with AATD.

Alpha1-Proteinase Inhibitor replacement
Subcutaneous and intravenous delivery
Pharmacokinetics and systemic exposure
Long-term safety in AATD

The sponsor also studies treatment effects in pulmonary emphysema linked to alpha-1-antitrypsin deficiency, with attention to preserving lung structure and limiting disease progression.

About Specializations

Grifols Therapeutics LLC runs clinical trials in conditions such as Chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma, Plasma cell myeloma, Emphysema, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

6 clinical trials

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo

Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Human Normal Immunoglobulin
Sponsor:Grifols Therapeutics LLC

Contact Research Centre

Alpha-1 antitrypsin deficiency

Recruiting

A study comparing under-the-skin and into-the-vein alpha1-proteinase inhibitor treatment in patients with alpha1-antitrypsin deficiency

InvestigationalNo placebo

A study comparing under-the-skin and into-the-vein alpha1-proteinase inhibitor treatment in patients with alpha1-antitrypsin deficiency

InvestigationalNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Human ALPHA1-PROTEINASE inhibitor
Sponsor:Grifols Therapeutics LLC

Contact Research Centre

Chronic lymphocytic leukaemia+2

Recruiting

Study on Human Normal Immunoglobulin and Sodium Chloride to Prevent Infections in Patients with Chronic Lymphocytic Leukemia

Registered drug

Study on Human Normal Immunoglobulin and Sodium Chloride to Prevent Infections in Patients with Chronic Lymphocytic Leukemia

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Grifols Therapeutics LLC

Contact Research Centre

Chronic lymphocytic leukaemia+2

Not yet recruiting

Clinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma

Registered drugNo placebo

Clinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Human Normal Immunoglobulin
Sponsor:Grifols Therapeutics LLC

Contact Research Centre

Emphysema

Not recruiting

Study on Long-term Safety of Weekly Intravenous Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1-Antitrypsin Deficiency

Registered drugNo placebo